Companion Diagnostics

Harness our technologies that unlock challenging regions of DNA and RNA with streamlined, multiplex workflows.

• Complex single nucleotide variants

• Pseudogene discrimination

• Gene conversions

• Methylation

Tap into our extensive portfolio of industry leading proteins, antibodies, and immunoassays with fit-for-purpose development and validation to eliminate commercial barriers and ensures long-term supply continuity. 

• Automated Simple Western and Simple Plex ELISAs 

• Olink® Target 96 Gold-certified service provider 

• Quantikine ELISAs and Luminex multiplex immunoassays

Stratify response to therapies and potential for segmentation in patient populations or understand therapy resistance leveraging our exosome-based platform.  

Exosomes are powerful diagnostic tools because they: 

• Are secreted by all living cells and number in the billions per milliliter. 

• Contain content reflective of the cell of origin allowing for non-invasive collection rather than tissue-only biopsy. 

• Are a stable sample amenable to frozen storage from CSF, plasma, or other biofluid. 

• Enables multiomic analysis of gene expression biomarkers, DNA variants (e.g. splice variants, fusions), and proteins to increase assay sensitivity

Asuragen, a Bio-Techne brand's AmplideX^® testing technology accelerates the journey from Clinical Trial Assay (CTA) to Companion Diagnostics (CDx) by reliably amplifying GC-rich and other repetitive DNA sequences to develop treatments for specific gene types. This accomplishment is shown through partnerships such as:

• Wave Life Sciences and Asuragen’s development of a CTA targeting the HTT gene 
• Zynerba and Asuragen’s partnership in the RECONNECT Trial for Fragile X Syndrome

The QuantideX^® technology can be adapted to monitor disease burden in diseases requiring highly sensitive detection and/or quantitation across multiple nucleic acid targets. It can also be utilized for designing high performing, efficient, and simplified kits for genetic targets with unmet biomarker development and CTA needs.

Exosomes can be integrated into your therapeutic development journey from translational biomarker discovery through downstream development of clinical trial assays and CDx products.

As exosomes pass through the blood-brain barrier, exosome-based diagnostics are likely to have considerable impact in Alzheimer’s and Parkinson’s diseases and other neurological conditions with high ​unmet need.

Blood-based liquid biopsies are making inroads in cancer management and are increasingly used in conjunction with tissue biopsies. Plasma cfDNA, ctDNA and exoRNA can be used to molecularly profile cancer patients and guide downstream treatment decisions.

Asuragen, a Bio-Techne brand, entered a partnership with Wave Life Sciences for the development and commercialization of companion diagnostics for Wave’s investigational allele-selective therapeutic programs targeting Huntington’s disease (HD).